|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | miR-182参与调节胶质母细胞瘤的凋亡、生长和分化(英文)显示文摘Glioblastoma multiforme(GBM)is a lethal,therapy-resistant brain cancer consisting of numerous tumor cell subpopulations,including stem-like glioma-initiating cells(GICs),which contribute to tumor recurrence following initial response to therapy.Here,we identified miR-182 as a regulator of apoptosis,growth,and differentiation programs whose expression level is correlated with GBM patient survival.Repression of Bcl2-like12(Bcl2L12),c-Met,and hypoxia-inducible factor 2α(HIF2A)is of central importance to miR-182 anti-tumor activity,as it results in enhanced therapy susceptibility,decreased GIC sphere size,expansion,and stemness in vitro.To evaluate the tumor-suppressive function of miR-182 in vivo,we synthesized miR-182-based spherical nucleic acids(182-SNAs);i.e.,gold nanoparticles covalently functionalized with mature miR-182 duplexes.Intravenously administered 182-SNAs penetrated the bloodbrain/blood-tumor barriers(BBB/BTB)in orthotopic GBM xenografts and selectively disseminated throughout extravascular glioma parenchyma,causing reduced tumor burden and increased animal survival.Our results indicate that harnessing the anti-tumor activities of miR-182 via safe and robust delivery of 182-SNAs represents a novel strategy for therapeutic intervention in GBM. | Kouri FM Hurley LA Daniel WL Day ES Hua Y Hao L Peng CY Merkel TJ Queisser MA Ritner C Zhang H James CD Sznajder JI Chin L Giljohann DA Kessler JA Peter ME Mirkin CA Stegh AH | 2015 | 中华神经外科疾病研究杂志2015，14，2： | 14 |
| 2 | Prevention and management of hepatitis B virus reactivation in patients with hematological malignancies treated with anticancer therapy显示文摘Hepatitis due to hepatitis B virus(HBV) reactivation can be severe and potentially fatal, but is preventable. HBV reactivation is most commonly reported in patients receiving cancer chemotherapy, especially rituximabcontaining therapy for hematological malignancies and those receiving stem cell transplantation. All patients with hematological malignancies receiving anticancer therapy should be screened for active or resolved HBV infection by blood tests for hepatitis B surface antigen(HBs Ag) and antibody to hepatitis B core antigen(antiHBc). Patients found to be positive for HBs Ag should be given prophylactic antiviral therapy to prevent HBV reactivation. For patients with resolved HBV infection, no standard strategy has yet been established to prevent HBV reactivation. There are usually two options. One is pre-emptive therapy guided by serial HBV DNA monitoring, whereby antiviral therapy is given as soon as HBV DNA becomes detectable. However, there is little evidence regarding the optimal interval and period of monitoring. An alternative approach is prophylactic antiviral therapy, especially for patients receiving highrisk therapy such as rituximab, newer generation of anti-CD20 monoclonal antibody, obinutuzumab or hematopoietic stem cell transplantation. This strategy may effectively prevent HBV reactivation and avoid the inconvenience of repeated HBV DNA monitoring. Entecavir or tenofovir are preferred over lamivudine as prophylactic therapy. Although there is no well-defined guideline on the optimal duration of prophylactic therapy, there is growing evidence to recommend continuing prophylactic antiviral therapy for at least 12 mo after cessation of chemotherapy, and even longer for those who receive rituximab or who had high serum HBV DNA levels before the start of immunosuppressive therapy. Many novel agents have recently become available for the treatment of hematological malignancies, and these agents may be associated with HBV reactivation. Although there is currently limited evidence to guide the optimal preventive measures, we recommend antiviral prophylaxis in HBs Ag-positive patients receiving novel treatments, especially the Bruton tyrosine kinase inhibitors and the phosphatidylinositol 3-kinase inhibitors, which are B-cell receptor signaling modulators and reduce proliferation of malignant B-cells. Further studies are needed to clarify the risk of HBV reactivation with these agents and the best prophylactic strategy in the era of targeted therapy for hematological malignancies. | Man Fai Law Rita Ho Carmen KM Cheung Lydia HP Tam Karen Ma Kent CY So Bonaventure Ip Jacqueline So Jennifer Lai Joyce Ng Tommy HC Tam | 2016 | World Journal of Gastroenterology2016，22，28： | 10 |
| 3 | 杏仁核-海马环路参与抑郁症的发病机制显示文摘慢性应激常可引发抑郁症。临床资料显示,抑郁症病人的腹侧海马CA1区(vCA1)n体积减小。vCA1是否参与抑郁症的发病?vCA1通过什么环路起作用?其分子机制如何?是本文要回答的科学问题。研究者利用慢性不可预见性温和应激(CUMS),构建小鼠抑郁症模型。主要结果如下:(1)与对照组相比,CUMS组vCA1中表达c-Fos的兴奋性神经元的比例降低。采用化学遗传学方法激活vCA1内兴奋性神经元,可明显缓解抑郁样行为。因此,海马vCA1内兴奋性神经元的活性降低,介导抑郁症的发生。 | 刘风雨(译) Ma H Li CY Wang JP | 2021 | 中国疼痛医学杂志2021，27，2： | 9 |
| 4 | Celecoxib-related gastroduodenal ulcer and cardiovascular events in a randomized trial for gastric cancer prevention显示文摘AIM: To evaluate the long-term risk of gastroduodenal ulcer and cardiovascular events induced by celecoxib in a population-based, randomized, double-blind, placebo-controlled study.METHODS: From 2004 to 2006, a total of 1024 Chinese patients (aged 35 to 64 years) with severe chronic atrophic gastritis, intestinal metaplasia or dysplasia were randomly assigned to receive 200 mg of celecoxib twice daily or placebo in Linqu County (Shandong Province, China), a high-risk area of gastric cancer. All gastroduodenal ulcer and cardiovascular events occurred were recorded and the patients were followed up for 1.5 years after treatment. At the end of the trial, a systematic interview survey about other adverse events was conducted. RESULTS: Gastroduodenal ulcer was detected in 19 of 463 (3.72%) patients who received celecoxib and 17 of 473 (3.31%) patients who received placebo, respectively (odds ratio = 1.13, 95% CI = 0.58-2.19). Cardiovascular (CV) events occurred in 4 patients who received celecoxib and in 5 patients who received placebo, respectively. Compared with those who received placebo, patients who received celecoxib had no signif icant increase in occurrence of CV events (hazard ratio = 0.84, 95% CI = 0.23-3.15). Among the adverse events acquired by interview survey, only the frequency of bloating was signif icantly higher in patients treated with celecoxib than in those treated with placebo. CONCLUSION: Treatment of gastric cancer with celecoxib is not associated with increased risk of gastroduodenal ulcer and cardiovascular events. | Guo-Shuang Feng Jun-Ling Ma Benjamin CY Wong Lian Zhang Wei-Dong Liu Kai-Feng Pan Lin Shen Xiao-Dong Zhang Jie Li Harry HX Xia Ji-You Li Shiu Kum Lam Wei-Cheng You | 2008 | World Journal of Gastroenterology2008，14，28： | 4 |
| 5 | Pulmonary function changes and increased Th-2 cytokine expression and nuclear factor κB activation in the lung after sensitization and allergen challenge in brown Norway rats显示文摘 | Lin CC Lin CY Ma HY | 2000 | Immunol Lett2000，73，1： | 1 |
| 6 | Updated population-based review of carcinoid tumors 显示文摘 | Maggard MA O' Connell JB Ko CY | 2004 | Ann Surg2004，240，1： | 1 |
| 7 | Targeting the tumor-associated folate receptor with an ^111In-DTPA conjugate of pteroic acid显示文摘 | Ke CY Mathias CJ Green MA | 2005 | J Am Chem Soc2005，127，20： | 1 |
| 8 | Expression of connexins 36,43, and 45 during postnatal development of the mouse retina显示文摘 | Kiahara AH Mantovani de Castro L Belmonte MA Yan CY Moriscot AS Hamassald DE | 2006 | J Neurobiol2006，66，13： | 1 |
| 9 | Ischemic postconditioning through per-cutaneous transluminal coronary angioplasty in pigs: roles of PI3 K acti-vation显示文摘 | Ma XJ Yin HJ Guo CY | 2012 | Coron Artery Dis2012，23，4： | 1 |
| 10 | A trial of darbepoetin al- fa in type 2 diabetes and chronic kidney disease 显示文摘 | Pfeffer MA Burdmann EA Chen CY | 2009 | N Engl J Med2009，361，21： | 1 |
| 11 | Ge- netic diversity and drug resistance among newly diagnosed and antiretroviral treatment-naive HIV-infected individuals in western Yunnan: a hot area of viral recombination in China 显示文摘 | Chen M Ma Y Duan S Xing H Yao S Su Y Luo H Yang L Chen H Fu L Qu A Ou CY Jia M Lu L | 2012 | BMC Infect Dis2012，12，： | 1 |
| 12 | Azospirillum isolated from within sporocarps of the mycorrhizal fungi Hebeloma crustuliniforme,Laccaria laccata and Rhizopogon unicolor显示文摘 | Li CY Castellano MA | | 0，，： | 1 |
| 13 | Colon cancer survival rates with the new American Joint Committee on Cancer sixth editionstaging显示文摘 | O'ConnellJB Maggard MA Ko CY | 2004 | J Natl Cancer Inst2004，96，19： | 1 |
| 14 | Construction of 4'-isovalerylspiramycin-I-producing strain by in-frame partial deletion of 3-O-acyltransferase gene in Streptomyces spiramyceticus WSJ-1,the bitespiramycin producer显示文摘 | Ma CY Zhou HX Li JY | | 0，，01： | 1 |
| 15 | Studies on the decontamination of air by plant显示文摘 | Comijo JJ Munoz FG Ma CY Stewart AJ | 1999 | Ecotoxicology1999，，8： | 1 |
| 16 | Updated population -based re- view of careinoid tumors显示文摘 | Maggard MA O'Connell JB Ko CY | 2004 | Ann Surg2004，240，1： | 1 |
| 17 | Updated population-based review of carcinoid tumors显示文摘 | Maggard MA O Connell JB Ko CY | 2004 | Ann Surg2004，240，1： | 1 |
| 18 | Crosslinking of biological tissues using genipin and/or carbodiimide显示文摘 | Sung HW Chang WH Ma CY | 2003 | Journal of Biomedical Materials Research Part A2003，64，： | 1 |
| 19 | Inhibition of endothelium-dependent vascular relaxation by tetrandrine显示文摘 | KWAN CY MA FM HUI SC | 1999 | Life Sci1999，64，25： | 1 |
| 20 | Evaluation of let) ventrieular twist in acute myocardial infarction patients using speckle tracking ima- ging 显示文摘 | Jia DL Ma CY Liu S | 2011 | Cell Biochem Biophys2011，61，3： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员